Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
On 11 July 2025, Haleon plc (LSE/NYSE: HLN) disclosed a TR-1 major shareholding notification from Wellington Management Group LLP. The investment manager’s aggregated interest fell from 5.87 % to 5.29 % of Haleon’s voting rights as of 10 July 2025, comprising 4.97 % held directly through ordinary shares (446.9 m votes) and 0.32 % via financial instruments (predominantly depository receipts and small equity swaps). The absolute position equals 475.6 m voting rights.
The reduction keeps Wellington above the critical UK 5 % disclosure threshold but signals incremental selling. No operational or earnings data are included; the filing is purely ownership-related.
Haleon plc (NYSE/LSE: HLN) has released unaudited historic pro-forma financials that restate 2023-2025 revenue under a new six-category reporting framework. The change, first signalled at the 1 May 2025 Capital Markets Day, splits the former “Digestive Health & Other” segment into two lines—Digestive Health and Therapeutic Skin Health & Other—and moves the Smokers Health franchise into Respiratory Health. Beginning with the Half-Year results on 31 July 2025, Haleon will report:
- Oral Health
- Vitamins, Minerals & Supplements (VMS)
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health & Other
Key restated figures (FY 2024 vs FY 2023):
- Total revenue £11.23 bn, down 0.6%; organic revenue growth +5.0%
- Oral Health £3.31 bn (+5.6% reported, +9.6% organic) – strongest absolute contributor
- VMS £1.70 bn (+3.4% reported, +7.6% organic) – solid rebound from 0.9% organic in 2023
- Pain Relief £2.56 bn (-3.3% reported, +0.1% organic) – softness after 7.4% organic in 2023
- Respiratory Health £2.12 bn (-5.4% reported, +1.0% organic) – lapping strong 2023 cold/flu season
- Digestive Health £1.03 bn (+1.7% reported, +5.5% organic)
- Therapeutic Skin Health & Other £0.51 bn (-17.5% reported, +9.8% organic) – large FX/disposal drag
Q1 2025 restated revenue shows modest momentum: total £2.85 bn (-2.3% reported, +3.5% organic) with Oral Health (+3.0% reported) and Pain Relief (-0.2% reported, +2.6% organic) leading. Geographical splits are unchanged and no guidance is updated in this filing.
The recast enhances transparency around category-level trends and is intended to align external reporting with strategic growth priorities ahead of Haleon’s first standalone medium-term targets expected at H1 results.
Haleon plc (LSE/NYSE: HLN) filed a Form 6-K reporting progress on the share buyback programme announced 28 March 2025.
Daily trade: on 25 June 2025 the company repurchased 1,006,111 ordinary shares at a volume-weighted average price of 383.38 pence (high 384.80 p, low 380.70 p). All shares will be cancelled.
Completion of first tranche: Haleon has now finished the programme’s first tranche, acquiring 51,036,522 shares for an aggregate consideration of about £200 million. The tranche equates to roughly 0.6 % of the current share base.
Updated share capital: issued share capital is 8,988,533,553 shares of £0.01 each. After deducting 4,080,205 treasury shares, voting shares total 8,984,453,348. Investors should use this figure for FCA disclosure-threshold calculations.
Next steps: management will announce any further tranches separately. The filing contains no earnings, guidance, or operational updates.